

Intersect ENT to Present at the 32nd Annual J.P. Morgan Healthcare Conference

Menlo Park, Calif. – Jan. 8, 2014 – Intersect ENT, Inc., an innovator in treatment solutions for ear, nose and throat clinicians and their patients, today announced that the company will present next week at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco.

Lisa Earnhardt, Intersect ENT's president and chief executive officer, will provide a company overview on Tuesday, January 14, 2014 at 7:30 a.m. PT in room Elizabethan C at the Westin St. Francis Hotel.

Intersect ENT's PROPEL[®] and PROPEL[®] mini implants are the first and only drug-eluting stents for patients with chronic sinusitis. The products release mometasone furoate, an advanced steroid with anti-inflammatory properties, directly into the sinus lining, then dissolve. Use of PROPEL maintains the open passages created in surgery leading to reduced need for oral medication and additional surgical procedures. The company is also studying a novel in-office solution for patients suffering from chronic sinusitis in a randomized clinical trial called the RESOLVE Study.

Chronic sinusitis is a condition in which patients' sinuses become swollen and inflamed, leading to difficulty breathing, facial pain or headache, and reduced sense of smell and taste. The condition is common, affecting 31 million people in the U.S., and greatly impacts quality of life. Chronic sinusitis often requires a complex combination of surgical and medical treatments. Each year, 500,000 patients undergo sinus surgery to treat the condition.

About Intersect ENT

Intersect ENT Inc., located in Menlo Park, Calif., is a growth-stage drug-device company focused on advancing clinically proven therapy solutions that improve quality of life for patients with ear, nose and throat conditions. The company's initial products, the PROPEL and PROPEL mini dissolvable steroid-releasing implants, are the only products backed by Level 1-A clinical evidence to improve sinus surgery outcomes for patients suffering from chronic sinusitis. Chronic sinusitis is a common condition that affects one out of seven adults in the U.S. and greatly impacts quality of life. The company holds twenty-three issued U.S. patents and more than 80 patents and pending applications worldwide. Intersect ENT is backed by Kleiner Perkins Caufield & Byers; U.S. Venture Partners; PTV Sciences; Norwest Venture Partners, and Medtronic. For more information please visit www.intersectENT.com.

###

Media Contact:

Nicole Osmer
650.454.0504
nicole@nicoleosmer.com